Significant Shift on Horizon for Pharmaceuticals - In-Depth Research Featuring RXi Pharmaceuticals and Poniard Pharmaceuticals

Mar 02, 2011, 09:06 ET from World Street Fundamentals

HONG KONG, March 2 /PRNewswire/ - Today, www.WorldStreetFundamentals.com released its report highlighting development-stage pharmaceutical companies, including RXi Pharmaceuticals Corporation (NASDAQ: RXII) and Poniard Pharmaceuticals, Inc. (NASDAQ: PARD). Global pharmaceutical market sales are expected to grow at a 4 - 7% compound annual growth rate (CAGR) through 2013, largely driven via growing access to health-care in emerging economic regions. Investors from around the world are invited to view fundamental and technical analysis at www.WorldStreetFundamentals.com.  

Significant shifts within the global pharmaceutical market are on the horizon, with trends growing towards the Asia-Pacific region. A favorable regulatory environment has started to emerge in India, China, Malaysia, South Korea and Indonesia; drawing the attention of larger API product providers. This new competition within an already fast-paced economy has closed the gap between product cost and disposable income of consumers - a change that is expected to drive long-term growth within the global marketplace.

The US market remains the largest pharmaceutical market in the world, and as such, is expected to fuel shot-term growth within the sector. Large focus on R&D in biotechnology, special drugs and generic drugs will remain a strong catalyst to meet 2011 targets of $315 billion dollar in sales volume within the United States alone. 

World Street Fundamentals has highlighted RXi Pharmaceuticals for its on focus on the RNA interference, a naturally occurring cellular mechanism that has the potential to effectively and selectively interfere with, or "silence", expression of targeted disease-associated genes. To read the report on RXi Pharmaceuticals Corporation (NASDAQ: RXII), visit www.WorldStreetFundamentals.com

World Street has recognized Poniard Pharmaceuticals, Inc. (NASDAQ: PARD)'s recent approval by the Chinese State Food and Drug Administration to conduct two Phase III clinical studies of its lead product candidate, picoplatin. China's market is expected to grow at rates exceeding 20%+ per annum for the next 3 years, and is one of the fastest growing markets in the industry today.   

To view fundamental and technical analysis on these two industry members we encourage investors to visit: www.WorldStreetFundamentals.com

About World Street
World Street Fundamentals is an online portal for professionals, investors and new-comers to the markets to find in depth comprehensive research and research tools to help guide you through the ever changing financial markets around the world. Covering the top performers in the hottest sectors and providing clarity to investors around the world.

SOURCE World Street Fundamentals